New York, New York--(Newsfile Corp. - August 14, 2026) - Kaplan Fox &amp; Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (&#34;Fulcrum Therapeutics&#34; or the

<p>New York, New York--(Newsfile Corp. - August 14, 2026) - <a href="https://api.newsfilecorp.com/redirect/GzpXWcyzwL">Kaplan Fox &#38; Kilsheimer LLP</a> is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/FULC">FULC</a>).</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/Q2zQ1s7Vny">CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION</a></p><p><b>If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may </b><a href="https://api.newsfilecorp.com/redirect/mj4QYc418g"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:jcampisi@kaplanfox.com"><b>jcampisi@kaplanfox.com</b></a><b> or by calling (212) 329-8571.</b></p><p>Fulcrum Therapeutics is a "clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with rare hematological disorders[.]"</p><p>On June 1, 2026, after market close, Fulcrum Therapeutics announced in a press release "the discontinuation of its pociredir program for the treatment of SCD [(sickle cell disease).]" The Company stated that the "meeting minutes from recent end-of-phase interactions with the [U.S. Food and Drug Administration ("FDA")]" "reflected heightened FDA concerns regarding pociredir's benefit-risk profile in SCD, stemming from an unexpectedly high rate of secondary hematologic malignancies observed with Tazverik&#174; (tazemetostat), another PRC2 inhibitor, which was withdrawn from the global market in March 2026." After submitting further information, the FDA "concluded that any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk regardless of the specific subunit engaged."  As a result, the Company has "no viable regulatory path forward for further clinical development of pociredir."</p><p>Following this news, the price of Fulcrum Therapeutics stock declined from a closing price on June 1, 2026 of $6.42 per share to close at $3.14 per share on June 2, 2026, a decline of $3.28 per share, or by 51.09%.</p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in <i>In re Bank of America</i>-the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act-$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a $475 million settlement in <i>In re Merrill Lynch</i>.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.</p><p>If you have any questions about this investigation, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b><br />Jeffrey P. Campisi<br /><a href="https://api.newsfilecorp.com/redirect/kXVJgCVEmB">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(212) 329-8571<br /><a href="mailto:jcampisi@kaplanfox.com">jcampisi@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/B5o0gcpQgw">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p><a href="https://api.newsfilecorp.com/redirect/5WVQvH5bMK">https://www.kaplanfox.com/case/fulcrum-therapeutics-inc-investigation-learn-more-now/</a></p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/309097_201a3765746a6948_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/LqN4xuDMb8">https://www.newsfilecorp.com/release/309097</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/309097/197" alt="" /></p>

FULC

Kaplan Fox & Kilsheimer LLP is Investigating Fulcrum Therapeutics, Inc. (FULC) for Possible Securities Law Violations

Kaplan Fox investigation adds risk to Fulcrum as FDA PRC2 concerns mount

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>New York, New York--(Newsfile Corp. - August 14, 2026) - Kaplan Fox &amp;amp; Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (&amp;#34;Fulcrum Therapeutics&amp;#34; or the</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Fulcrum disclosed discontinuing pociredir for sickle cell disease after FDA concerns about PRC2 inhibitors&#039; risk profile. Kaplan Fox launched a securities investigation, raising potential legal/issuer scrutiny. The stock plunged about 51% from June 1 to June 2, signaling near-term downside tied to pipeline feasibility and any regulatory or legal developments.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Kaplan Fox investigating Fulcrum securities violations; investor action possible.</li><li>Fulcrum discontinues pociredir for SCD following FDA concerns.</li><li>FDA concludes PRC2 targeting carries malignancy risk; no viable regulatory path.</li><li>Stock collapsed 51% from $6.42 to $3.14 (June 1–2, 2026).</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Fulcrum Therapeutics, Inc. (FULC)</strong>: Discontinued pociredir program for SCD; pipeline risk and regulatory headwinds weigh on valuation.</li><li><strong>Kaplan Fox &amp; Kilsheimer LLP (N/A)</strong>: Leading securities-litigation firm launching investigation; potential claims could raise leverage on disclosures.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. The piece centers on an external law-firm securities investigation tied to Fulcrum and a major regulatory setback for a lead program, making legal/regulatory risk a primary lens for short-term price action.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>FDA PRC2 risk concerns weigh on pociredir and broader pipeline outlook.</li><li>Fulcrum stock fell 51% after the June 1 announcement.</li><li>Kaplan Fox securities investigation may attract investor attention and optimism for claims.</li><li>Regulatory/legal catalysts could sustain volatility in FULC shares.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date: June 1, 2026 – Fulcrum announces discontinuation of pociredir for SCD after market close.</li><li>FDA end-of-phase interactions cited heightened concerns; expected malignancy risk with PRC2 inhibitors.</li><li>FDA concluded any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk.</li><li>June 1 close: $6.42; June 2 close: $3.14; decline of $3.28, or 51.09%.</li><li>Date: August 14, 2026 – Kaplan Fox &amp; Kilsheimer LLP announces investigation.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bearish near-term; potential for further downside over the next 1–3 months as catalysts unfold.</p>
  </section>
</section>


<p>New York, New York--(Newsfile Corp. - August 14, 2026) - <a href="https://api.newsfilecorp.com/redirect/GzpXWcyzwL">Kaplan Fox &#38; Kilsheimer LLP</a> is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/FULC">FULC</a>).</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/Q2zQ1s7Vny">CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION</a></p><p><b>If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may </b><a href="https://api.newsfilecorp.com/redirect/mj4QYc418g"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:jcampisi@kaplanfox.com"><b>jcampisi@kaplanfox.com</b></a><b> or by calling (212) 329-8571.</b></p><p>Fulcrum Therapeutics is a "clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with rare hematological disorders[.]"</p><p>On June 1, 2026, after market close, Fulcrum Therapeutics announced in a press release "the discontinuation of its pociredir program for the treatment of SCD [(sickle cell disease).]" The Company stated that the "meeting minutes from recent end-of-phase interactions with the [U.S. Food and Drug Administration ("FDA")]" "reflected heightened FDA concerns regarding pociredir's benefit-risk profile in SCD, stemming from an unexpectedly high rate of secondary hematologic malignancies observed with Tazverik&#174; (tazemetostat), another PRC2 inhibitor, which was withdrawn from the global market in March 2026." After submitting further information, the FDA "concluded that any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk regardless of the specific subunit engaged."  As a result, the Company has "no viable regulatory path forward for further clinical development of pociredir."</p><p>Following this news, the price of Fulcrum Therapeutics stock declined from a closing price on June 1, 2026 of $6.42 per share to close at $3.14 per share on June 2, 2026, a decline of $3.28 per share, or by 51.09%.</p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in <i>In re Bank of America</i>-the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act-$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a $475 million settlement in <i>In re Merrill Lynch</i>.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.</p><p>If you have any questions about this investigation, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b><br />Jeffrey P. Campisi<br /><a href="https://api.newsfilecorp.com/redirect/kXVJgCVEmB">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(212) 329-8571<br /><a href="mailto:jcampisi@kaplanfox.com">jcampisi@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/B5o0gcpQgw">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p><a href="https://api.newsfilecorp.com/redirect/5WVQvH5bMK">https://www.kaplanfox.com/case/fulcrum-therapeutics-inc-investigation-learn-more-now/</a></p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/309097_201a3765746a6948_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/LqN4xuDMb8">https://www.newsfilecorp.com/release/309097</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/309097/197" alt="" /></p>

Fulcrum disclosed discontinuing pociredir for sickle cell disease after FDA concerns about PRC2 inhibitors' risk profile. Kaplan Fox launched a securities investigation, raising potential legal/issuer scrutiny. The stock plunged about 51% from June 1 to June 2, signaling near-term downside tied to pipeline feasibility and any regulatory or legal developments.

News insight

Kaplan Fox & Kilsheimer LLP is Investigating Fulcrum Therapeutics, Inc. (FULC) for Possible Securities Law Violations

AI summary

Sentiment rationale

Key facts

Legal